Astragaloside IV potentiates cisplatin sensitivity in triple-negative breast cancer via STING signaling pathway activation

作者：Bufan Bai, Luyao Zhang, Yifei Zhang, Rushuang Yue, Yi-Yu Lu, Rong Shi, Qianmei Zhou · 发表于：Phytomedicine · 年份：2025 · DOI：10.1016/j.phymed.2025.157330 · 被引用次数：3 · 研究领域：interferon and immune responses、Ferroptosis and cancer prognosis、vaccines and immunoinformatics approaches

• The efficacy of cisplatin in triple-negative breast cancer (TNBC) is limited by several critical challenges. Astragaloside IV synergistically enhances the therapeutic efficacy of cisplatin against TNBC while ameliorating its adverse effects. • Integrating bioinformatics analysis (WGCNA, LASSO, and CIBERSORT), transcriptomic and molecular docking analysis, we speculated on the potential pharmacological substances and investigated that the mechanism of astragaloside IV was related to the activation of STING and immune. • These findings offer molecular validation for the observed "Qi-tonifying" properties of astragaloside IV in traditional Chinese medicine (TCM), bridging TCM with contemporary immunopharmacology. It demonstrates that fortifying endogenous defense mechanisms - particularly immune function - constitutes an effective anticancer strategy. Astragaloside IV (As), a bioactive tetracyclic triterpenoid saponin from Astragalus membranaceus, exhibits diverse pharmacological properties including anti-inflammatory, anticancer and immunomodulatory activities. However, its potential role as a targeted therapeutic agent for cisplatin sensitization in triple-negative breast cancer (TNBC) via the STING signaling pathway remains unexplored. This study aimed to investigate the cisplatin-sensitizing potential of As in TNBC and elucidate its underlying molecular mechanisms. Bioinformatic analysis identified key module genes from public databases using weighted gene co-expression ne...